INTRODUCTION

Recent reports reveal that breast cancer (BC) is a leading cause of death resulting from cancer in Caribbean women. Studies examining exogenous and genetically predetermined endogenous risk factors are critical to define breast cancer susceptibility in Caribbean women. The purpose of this systematic review is to assess the existing scientific literature in the last 42 years (1975 to 2017) to describe the body of research generated for the population of this region and determine future research directions.

METHODS

Literature Review and Inclusion and Exclusion Criteria

This analysis includes relevant publications in PubMed from inception to January 2017 using
the search terms “breast cancer and Caribbean” and “breast cancer and [individual country name]” for all Caribbean countries (Appendix). The bibliographies of several review articles were examined to identify additional publications that might have been missed by our PubMed search. Abstracts and full texts were reviewed by three independent reviewers and cross-referenced to address discrepancies and confirm eligibility for inclusion. For overlapping studies, the publication with the largest population and/or most complete information was included. All population-based analyses (case-cohort, cross-sectional, case-control, qualitative, and other observational studies) of BC in a Caribbean population were considered. Studies comparing Caribbean data with those on other populations in different geographic regions were included, but only data on indigenous Caribbean women are reported. Studies conducted in basic science or immigrant Caribbean populations and non-English articles were excluded. Screening prevalence rates in Caribbean women were reported in our previous review13 and therefore were excluded from this analysis, with the exception of publications that reported factors associated with screening. On the basis of these inclusion and exclusion criteria, data from 92 publications were included in this analysis (Fig 1).

**Data Collection**

From each publication, first author, publication year, topic of research focus, study sample size, and reported key findings were abstracted. The number of publications by country was examined, and countries were categorized as high (≥ 10 publications), intermediate (five to nine publications), or low (one to four publications).

For estimates of BC incidence and mortality, GLOBOCAN 20122 was used for the Caribbean and other world regions (for comparison). Incidence trends by age were also examined for each Caribbean nation and compared with world incidence trends. All incidence and mortality rates are reported as age standardized to the world population.

**RESULTS**

**Estimated Incidence and Mortality of BC in Caribbean Populations**

In all geographic regions, BC incidence was higher than mortality (Fig 2). The lowest BC incidence and mortality rates are estimated in Haiti.
(22.0 and 11.5 per 100,000, respectively) and the highest in the Bahamas (98.9 and 26.3 per 100,000, respectively). When age-specific incidence was examined, a majority (11 [79%] of 14) of Caribbean countries had peaks in BC incidence that were similar (age, 65 to 69 years) or at an older age (age, 70 to 74 years) than world estimates (peak at age 65 to 69 years). Among these Caribbean countries, Suriname, the Bahamas, and Guadeloupe had a second peak in BC incidence at < 60 years of age (age 45 to 49, 50 to 54, and 55 to 59 years, respectively). Only French Guiana, Dominican Republic, and Belize had a peak in BC incidence at a younger age (age 55 to 59 years).

Status of BC Research in Caribbean Populations

From 1975 to 2017, 92 publications on BC research in the Caribbean region were identified, with an increase in frequency from the 1990s (Fig 3). Most articles focused on epidemiologic trends and clinicopathologic features. It was not until 2007 that an expansion of research focus was observed (Fig 3). Sixteen (53%) of 30 Caribbean countries were documented in publications focusing on BC in native Caribbean women, with a majority having intermediate to low numbers of publications (Fig 4).

A majority (82 [89.1%] of 92) of publications involved one or more Caribbean coauthors, and
many involved coauthors in other geographic regions. Most Caribbean researchers were the first author (66 [80.5%] of 82) on each publication, and a smaller proportion (61 [74.4%] of 82) were the corresponding author.

Key Findings From Caribbean BC Studies

Key findings of BC research in the Caribbean are summarized in Table 1. Sample size in these publications ranged from 16 to 9,389 women.

**Descriptive cancer trends (incidence and mortality).** Eight publications from 1992 to 2016 described regional analyses of epidemiologic trends in incidence and/or mortality.\(^1\)\(^{14-20}\) All of them suggested that BC was both the leading cancer site and cause of death resulting from cancer. Similar findings, using data from pathology databases or hospital or national cancer registries, were also published\(^21\)\(^-\)\(^{50}\) and highlighted: earlier age at diagnosis in Barbados (age 50 to 54 years) in contrast to US black women (age 75 to 79 years)\(^{24}\); increasing BC incidence in Jamaica from 1958 to 1992,\(^{54,36}\) followed by relatively stable incidence rates from 1993 to 2007\(^{37,39,40}\); lower BC incidence in Puerto Rico from 1969 to 2003 in comparison with mainland United States\(^{46,47}\) and higher incidence and mortality rates in areas with high socioeconomic status\(^{43}\); similarly, from 1994 to 2003, lower BC incidence in Suriname than in the United States\(^{48}\); and increasing BC mortality in Trinidad and Tobago (henceforth, Trinidad) from 1970 to 2003,\(^{49}\) with geographic residence and African ancestry emerging as strong predictors of BC incidence and mortality.\(^{50}\)

**Clinicopathologic features.** Eighteen publications described clinicopathologic features of women from seven Caribbean countries (the Bahamas, Cuba, Guadeloupe, Jamaica, Puerto Rico, Suriname, and Trinidad).\(^{51-67,105}\) The most common histologic type was infiltrating ductal carcinoma. For countries that reported staging data, stage ≥ 2 at presentation was reported in Barbados,\(^54\) Jamaica,\(^54,56\) and Trinidad.\(^57\) In contrast, one study in Puerto Rico reported that 88.9% of patients presented with stage I to III and T1/T2 BC.\(^{60}\) Multiple studies of hormone receptor status
Table 1. Key Findings From BC Research Studies of Caribbean Populations

| First Author | Country | Year of Publication | Study Size | Key Findings |
|--------------|---------|---------------------|------------|--------------|
| Brooks14     | Caribbean, NOS | 1992 | NA | NA |
| Ivey15       | Caribbean, NOS | 2008 | NA | BC among leading causes of death resulting from cancer in 21 Caribbean countries |
| Luciani16    | Caribbean, NOS | 2013 | 2,695 cases | In 16 Caribbean countries, top five countries with highest age-standardized mortality rates (2004-2008) for BC are St Vincent and the Grenadines, the Bahamas, St Kitts/Nevis, Trinidad and Tobago, and Antigua/Barbuda |
| Razzaghi1     | Caribbean, NOS | 2016 | 3,773 cases | From 2003 to 2013, for all Caribbean countries, BC was leading cause of death resulting from cancer, accounting for 21.8% of deaths resulting from cancer in women (highest: Cayman Islands, 29.7%; the Bahamas, 28.8%; lowest: Belize, 14.0%; Suriname 16.1%) |
| Robles17     | Caribbean, NOS | 2002 | NA | Relatively high mortality/incidence ratios; BC cases not being adequately managed in many Latin America and Caribbean countries |
| Bosetti18     | Caribbean, NOS | 2005 | 1,350 cases | Among two Latin Caribbean countries from 1970 to 2000, similar mortality rates observed in Cuba (28.22%) and Puerto Rico (27.96%) for women age < 65 years, with Cuba having stable mortality rates |
| Chatenoud19   | Caribbean, NOS | 2014 | 1,695 cases | Among two Latin Caribbean countries from 2005 to 2009, similar mortality rates observed in Cuba (14.89%) and Puerto Rico (12.57%), with Cuba having stable mortality rates |
| Di Sibio20    | Caribbean, NOS | 2016 | 1,934 incident cases | For Latin Caribbean and South American Caribbean countries (2003-2008), BC was leading incident female cancer in Belize and second leading cause of death resulting from cancer in Belize and Cuba |
| Simon21       | Antigua and Barbuda | 1991 | 139 incident cases | BC is main cancer diagnosed (23.1%) and cause of death among these (18.2%) |
| Brathwaite22  | Bahamas | 1984 | NA | BC is most frequent female cancer (45.3%) and most frequent cause of death among these (19.2%) |
| Brathwaite23  | Bahamas | 2007 | 358 incident cases | BC is most frequent cancer in women |
| Dallaire26    | Barbados | 2009 | 396 cases | Incidence peaked at earlier age among Barbadian women (age 50-54 years) in contrast to African American women (age 75-79 years) |
| Martin27      | Cuba | 1998 | 8,579 cases | BC is among top five cancers in incidence and mortality (1986-1990) |
| Graupera Boschmonar28 | Cuba | 1999 | 2,371 cases | 3-year survival rate for BC in Cuba, 61% (1988-1989) |
| Galán29       | Cuba | 2009 | 2,445 cases | BC is leading cancer in incidence (2001-2003) and second leading cause of death resulting from cancer in women (2005-2007) |
| Garrote30     | Cuba | 2011 | NA | 5-year age-standardized relative survival for BC, 69% (1994-1995) |

(Continued on following page)
Table 1. Key Findings From BC Research Studies of Caribbean Populations (Continued)

| First Author      | Country          | Year of Publication | Study Size | Key Findings                                                                                                                                 |
|-------------------|------------------|---------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Domínguez30       | Cuba             | 2014                | NA         | Unfavorable trend in disability-adjusted life-years seen for BC between 1990 and 2006 in Cuban women of childbearing age                       |
| Shai31            | Cuba             | 1991                | NA         | Lower BC mortality compared with US women                                                                                                    |
| Asulin32          | Grenada          | 2004                | NA         | BC among top four frequently diagnosed cancers and most frequent cause of mortality in women                                                |
| Best Plummer33    | Guyana           | 2009                | 589 cases  | Among women, Indo-Guyanese presented with most cases of BC (45%) compared with Afro-Guyanese women                                           |
| Harris34          | Jamaica          | 1977                | NA         | Upward annual incidence trend observed from 1958 to 1974; BC conforms to Western pattern with regard to shape of age-specific incidence curve and stage of presentation; no obvious histologic differences between BC in Africa, Jamaica, and United States |
| Brooks35          | Jamaica          | 1991                | 2,837 cases| In women, 24.1% of cancers occurred in breast (1958-1987)                                                                                   |
| Brooks36          | Jamaica          | 1995                | 582 cases  | From 1988 to 1992, increase in female BC (crude rate, 36.0; ASR, 47.1)                                                                       |
| Hanchard37        | Jamaica          | 2001                | 627 cases  | From 1993 to 1997, in women, leading cancer site was breast (627 [26.7%] of 2,344); incidence remained relatively stable (ASR, 43.2 v 47.1 per 100,000 per year) |
| Blake38           | Jamaica          | 2002                | 291 cases  | BC among leading cancer mortality sites in women                                                                                              |
| Gibson39          | Jamaica          | 2008                | 639 cases  | From 1998 to 2002, in women, leading cancer site was breast (639 [27.1%] of 2,350); incidence remained relatively stable (ASR, 43.2 v 40.1 per 100,000 per year) |
| Gibson40          | Jamaica          | 2010                | 720 cases  | From 2003 to 2007, in women, leading cancer site was breast; incidence remained relatively stable (ASR, 40.1 v 43 per 100,000 per year)         |
| Dieye41           | Martinique       | 2007                | 1,568 cases| BC most common cancer diagnosed in women                                                                                                      |
| Freni42           | Netherlands Antilles | 1981            | 338 cases  | Cancer in women most frequently found in breast                                                                                               |
| Torres-Cintrón43  | Puerto Rico      | 2012                | NA         | Incidence and mortality rates for BC higher for areas with highest socioeconomic position                                                   |
| O’Neil44          | Puerto Rico      | 2015                | 9,389 cases| Average annual incidence of BC among women, 84 per 100,000 women (2007-2011)                                                                   |
| Nazario45         | Puerto Rico      | 2000                | 4,289 cases| Lifetime risk of BC seems to be increasing in Puerto Rico                                                                                  |
| Martinez46        | Puerto Rico      | 1975                | 871 cases  | From 1969 to 1971, age-specific incidence of BC lower in Puerto Rico compared with United States                                             |
| Ortiz47           | Puerto Rico      | 2010                | NA         | From 1992 to 2004, BC incidence lower than in United States and other ethnic groups, but mortality is similar                                 |
| van Leeuwaarde48  | Suriname         | 2011                | 421 cases  | From 1994 to 2003, BC incidence in Suriname is low compared with that in Western world, but advanced stage at diagnosis; 5-year OS, 79%   |
| Naraynsingh49     | Trinidad and Tobago | 2010            | 2,689 cases| From 1970 to 2004, BC mortality continued to increase over 35-year period in Trinidad and Tobago                                             |
| Warner50          | Trinidad and Tobago | 2015              | 3,767 cases| From 1995 to 2007, West African ancestry and geographic residence seemed to be strong predictors of BC incidence and mortality rates   |

(Continued on following page)
Table 1. Key Findings From BC Research Studies of Caribbean Populations (Continued)

| First Author | Country                  | Year of Publication | Study Size | Key Findings                                                                                                                                                                                                 |
|--------------|--------------------------|--------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Mungrue51    | Bahamas                  | 2016               | 270 cases  | Ductal carcinoma was most common; most cancers occurring at grade ≥ 2 and presenting as late stage (stage ≥ II); New Providence had highest occurrence of BC among all islands of the Bahamas                                                   |
| Alvarez Goyanes52 | Cuba              | 2010               | 1,509 cases | 72% of tumors expressed some level of hormone dependency; 53% were ER positive and 49% were PR positive (ER positive/PR positive, 38%; ER negative/PR negative, 28%; ER positive/PR negative, 23%; ER negative/PR positive, 11%) |
| Deloumeaux53  | Guadeloupe               | 2017               | 1,275 cases | ER positive/PR positive, 65.1%; ER negative/PR negative, 20.1%; TNBC accounted for 14% of all cases and was more frequent in patients age < 40 years; 5-year survival, 84.9% (survival was higher for HR positive/HER2/neu positive and HR positive/HER2/neu negative subtypes and lower for HR negative/HER2/neu positive subtype and TNBC) |
| Pott54       | Jamaica                  | 1978               | NA         | Considerable number of patients with stage II and III disease; histologic type most frequently seen is infiltrating duct carcinoma                                                                               |
| Shirley65    | Jamaica                  | 2008               | NA         | Patient presentation at relatively advanced stages of disease                                                                                                                                                    |
| Shirley56    | Jamaica                  | 2010               | 762 cases  | Patient presentation at relatively advanced stages of disease                                                                                                                                                    |
| Alfred57     | Jamaica                  | 2012               | 243 cases  | ER positive, 63%; ER negative, 37%; ER-negative group was older                                                                                                                                               |
| Peredo56     | Puerto Rico              | 2001               | 143 cases  | 28 overexpressed HER2/neu (19.6%); of HER2/neu-negative patients, 30 (26%) of 114 were ER negative compared with nine (33%) of 27 (P = .464); in progesterone specimens negative for HER2/neu, 44 (39%) of 114 were HER2/neu negative v 15 (56%) of 27 (P = .108) |
| Colón59      | Puerto Rico              | 2002               | 309 cases  | ER positive, 65.9%; PR positive, 51.8%; HER2/neu, 27.8%                                                                                                                                                      |
| Giraldo-Jiménez60 | Puerto Rico          | 2012               | 54 cases   | 51 had stage I to III presentation; T1/T2 tumors were found in 88.9% and absence of nodal involvement in 68.5%; 5-year OS and PFS were 81% and 80%, respectively                                                                 |
| Ortiz51      | Puerto Rico              | 2013               | 663 cases  | 17.3% of BC cases were TN; 61.8% were luminal A; 13.3% were luminal B; 7.5% were HER2 overexpressed; TN subtype and HER2-positive tumors were associated with decreased survival                                                  |
| Agosto-Arroyo52 | Puerto Rico           | 2015               | 487 cases  | Molecular categories were 66%, 10%, 9%, and 15% for luminal A, luminal B, HER2, and TN groups, respectively                                                                                                  |
| Brathwaite63  | Suriname                 | 1979               | 242 cases  | Mean age, 55.1 years; histologic types included scirrhous (40.9%), unclassified infiltrating duct (41.3%), medullary (4.5%), infiltrating comedo (3.7%), infiltrating lobular (3.3%), undifferentiated (2.5%), intraduct (1.2%), sarcoma (1.6%), and infiltrating papillary (0.8%) |
| Raju64       | Trinidad and Tobago      | 1989               | NA         | Multiparous, 85%; average of four children, and 92% of them breast fed; infiltrating duct carcinoma most frequent histologic diagnosis; LC seen in 1% of cases                                                                 |

(Continued on following page)
Table 1. Key Findings From BC Research Studies of Caribbean Populations (Continued)

| First Author | Country       | Year of Publication | Study Size | Key Findings                                                                                                                                                                                                 |
|--------------|---------------|---------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Jack65       | Trinidad and Tobago | 2000               | 111 cases  | Infiltrating duct carcinoma, 32%; IDC, 29%; adenocarcinoma, 12%; and LC and papillary carcinoma, 27%                                                                                                      |
| Rao66        | Trinidad and Tobago | 2002               | 103 cases  | ER positive, 54%; PR positive, 46%; c-erbB-2, 63%; ER negative/PR negative, 41%                                                                                                                            |
| Mungrue67    | Trinidad and Tobago | 2014               | 640 cases  | Stage IIA BC most common presenting stage (n = 154; 24%); IDC most common histologic type (n = 429; 67%)                                                                                               |
| Dindyal68    | Trinidad and Tobago | 2004               | 299 cases  | IDC most commonly occurring histologic type (70%), with ILC accounting for 17%; Afro-Caribbean women twice as likely to develop IDC and ILC compared with Indo-Caribbean women; less common (medullary, 4%; papillary, 2%; and mucinous adenocarcinoma types, 3%) and other rare histologic types (< 4%) were squamous, tubular, and comedo carcinomas, sarcoma, mesenchymal chondrosarcoma, and phyllodes tumor |
| Nemesure69   | Barbados      | 2009               | 222 cases  | In some but not all patients, body size factors play role in BC risk; older age may affect these relationships                                                                                        |
| Fernández70  | Cuba          | 1986               | 438 cases  | Older age, late menarche, and late parity associated with BC                                                                                                                                               |
| Kadhel71     | Guadeloupe/ Martinique | 2014           | 1,494 cases | Largest numbers of expected cases occurring in women between ages 45 and 54 years                                                                                                                        |
| Brady-West72 | Jamaica       | 2000               | 120 cases  | Risk factors: early menarche (5.5%), nulliparous (30%), first live birth after age 30 years (5%), ≥ one affected first-degree relative (12.5%); 54% of patients possessed no risk factors examined in this study, 36% had single risk factor, and 10% had two risk factors; larger studies should be encouraged to identify additional risk factors and degree to which published predictive variables are applicable |
| Santiago73   | Puerto Rico   | 1998               | 18 cases   | Nonsignificant positive associations between total fat and different components of dietary fat and postmenopausal BC                                                                                     |
| Morales74    | Puerto Rico   | 2014               | 465 cases  | ER positive, 75%; PR positive, 66.9%; HER2/neu negative, 76.8%; increased risk factors for BC: low DRC, age > 61 years, family history of BC, low education level; decreased risk factors for BC: endometriosis, parity at early age, higher parity, hysterectomy age < 50 years, multivitamin and calcium intake, and longer duration of breastfeeding |
| Joseph75     | Trinidad and Tobago | 2014          | 131 cases  | Analysis confirms that breast density is important predictor of newly diagnosed BC in this Caribbean population                                                  |
| Naraynsingh76 | Trinidad and Tobago | 2011         | 331 cases  | Early hospital discharge after BC surgery is feasible option for most patients and can be safely implemented even in resource-limited setting where cost containment is essential |

Epidemiologic risk factors

| Nemesure69  | Barbados | 2009 | 222 cases | 454 controls | In some but not all patients, body size factors play role in BC risk; older age may affect these relationships |
| Fernández70 | Cuba     | 1986 | 438 cases | 449 controls | Older age, late menarche, and late parity associated with BC |
| Kadhel71    | Guadeloupe/ Martinique | 2014 | 1,494 cases | Largest numbers of expected cases occurring in women between ages 45 and 54 years |
| Brady-West72| Jamaica  | 2000 | 120 cases | Risk factors: early menarche (5.5%), nulliparous (30%), first live birth after age 30 years (5%), ≥ one affected first-degree relative (12.5%); 54% of patients possessed no risk factors examined in this study, 36% had single risk factor, and 10% had two risk factors; larger studies should be encouraged to identify additional risk factors and degree to which published predictive variables are applicable |
| Santiago73  | Puerto Rico| 1998 | 18 cases | 18 controls | Nonsignificant positive associations between total fat and different components of dietary fat and postmenopausal BC |
| Morales74   | Puerto Rico| 2014 | 465 cases | 661 controls | ER positive, 75%; PR positive, 66.9%; HER2/neu negative, 76.8%; increased risk factors for BC: low DRC, age > 61 years, family history of BC, low education level; decreased risk factors for BC: endometriosis, parity at early age, higher parity, hysterectomy age < 50 years, multivitamin and calcium intake, and longer duration of breastfeeding |
| Joseph75    | Trinidad and Tobago | 2014 | 131 cases | 2,415 controls | Analysis confirms that breast density is important predictor of newly diagnosed BC in this Caribbean population |
| Naraynsingh76 | Trinidad and Tobago | 2011 | 331 cases | Early hospital discharge after BC surgery is feasible option for most patients and can be safely implemented even in resource-limited setting where cost containment is essential |
### Table 1. Key Findings From BC Research Studies of Caribbean Populations (Continued)

| First Author        | Country                  | Year of Publication | Study Size | Key Findings                                                                                                                                 |
|---------------------|--------------------------|--------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Camacho-Rivera77    | Trinidad and Tobago       | 2015               | 2,614 cases | Advanced-stage disease and negative HRS independently significantly associated with poorer survival outcome                                |
| Taioli78            | Trinidad and Tobago       | 2010               | 3,710 cases | Study suggests that biologic, behavioral, environmental, and clinical factors play significant roles in observed difference in BC outcomes in women of Afro-Caribbean descent |
| Roué79              | French Guiana             | 2016               | 269 cases   | Place of birth, mode of diagnosis, tumor stage at diagnosis, histologic type, and HRS associated with BC-specific survival                   |
| Skoog80             | Cuba                      | 1987               | 296 cases   | Axillary lymph node status and ER cellular content most important prognostic factors                                                           |
| Ríos81              | Cuba                      | 1988               | 225 cases   | ER and EGFR receptor status lead to increased prognostic predictive capacity; patients with ER-positive EGFR-positive disease have relapse rates similar to those with ER-negative disease and are thus high-risk patients; patients with ER-positive EGFR-negative disease have good prognosis |
| Walters82           | Jamaica                   | 1994               | 62 cases    | Clinical staging inadequate for management of stage I BC; consistent pathologic staging, use of other prognostic predictors, and systemic therapy on more widespread scale may help improve clinical outcome |

#### Behavioral risk factors

| Gibbon83            | Cuba                      | 2011               | 250 cases   | Drawing on qualitative data examining health beliefs in relation to BC, findings presented here suggest that although family history may be perceived as risk factor for many diseases (not just BC), genetic risk has little meaningful resonance for many participants |
| Delpech84           | Grenada                   | 2015               | 110 controls| Motivation to perform BSE associated with younger age and church attendance; perceived susceptibility associated with marital status and frequency of church attendance; perceived benefit associated with marital status, church attendance, and frequency of attendance |
| Menvielle85         | Guadeloupe/Martinique     | 2016               | 4,054 controls| Higher BC screening participation reported among participants having hot water at home and having visited GP during last year               |
| Anakwenze86         | Jamaica                   | 2015               | 246 controls| Greatest post-test improvements among items measuring knowledge of BC screening tests and risk factors; use of theory-based educational intervention positively influenced knowledge of BC risk factors, symptoms, and types of screening and increased screening rates in screening-naïve women |
| Tirado-Gómez87      | Puerto Rico               | 2016               | 50 cases    | Low levels of physical activity being practiced by group of Puerto Rican BC survivors, despite fact that many of them had access to exercise equipment and facilities |
| Underwood88         | US Virgin Islands         | 2007               | 178 controls| Provider communication significantly influenced BC screening practices and receptivity to BC risk management of study participants; participants who reported having had discussions with health care providers about their BC risk were more likely to express willingness to consider risk management strategies |

(Continued on following page)
### Table 1. Key Findings From BC Research Studies of Caribbean Populations (Continued)

| First Author | Country            | Year of Publication | Study Size | Key Findings |
|--------------|--------------------|--------------------|------------|--------------|
| Peltzer89    | Barbados/Grenada   | 2014               | 517 controls | Among university students in Barbados, most frequently cited risk factors were genetics, stress, and smoking; in Grenada, most frequently cited risk factors were genetics, smoking, and dietary fat/overweight |
| Kadhel90     | Guadeloupe/Martinique | 2016            | 115 cases | In BC survivors, most frequently cited risk factors were stress, genetic causes, and poor diet |
| Sharma91     | Haiti              | 2013               | 123 cases | Interventions needed to educate patients on recognition of initial BC signs and symptoms and address cost concerns by providing care free of charge and/or advertising that existing care is already free |
| O’Neill92    | Haiti              | 2015               | 61 cases | Despite receiving free care, > two thirds of participants spent > 40% of their potential household income on out-of-pocket expenses |
| Chirikos93   | Puerto Rico        | 2007               | 1,450 cases | Previously underserved women being treated for BC at rate roughly on par with other patients |
| Sánchez Ayéndez94 | Puerto Rico    | 2001              | 500 controls | Referral from physician most important factor for mammogram compliance |
| Modeste95    | Trinidad and Tobago | 1999            | 265 controls | Barriers to early detection identified were low level BSE, infrequent clinical breast examinations as part of regular care, unavailability of mammography services on Tobago, cost of screening, and difficulty of traveling to Trinidad for mammography |
| Gosein96     | Trinidad and Tobago | 2014            | 314 controls | 76.8% of participants knew that family history of BC was risk factor; obesity and alcohol consumption were less well-known risk factors, with only 29.3% and 12.4% agreeing, respectively; nearly two-thirds (63.7%) incorrectly believed breast trauma to be risk factor |

### Genetic risk factors and molecular biomarkers

| First Author | Country | Year of Publication | Study Size | Key Findings |
|--------------|---------|--------------------|------------|--------------|
| Akbari97     | Bahamas | 2014               | 214 cases | Approximately 27% of unselected BC cases attributable to mutation in BRCA1 or BRCA2 |
| Trottier98   | Bahamas | 2015               | 202        | To offer genetic testing to relatives of patients with BC with BRCA mutations, direct contact by genetic counselor preferable to using proband as intermediary |
| Trottier99   | Bahamas | 2016               | 1,847 controls | BRCA mutations were found in 2.8% (20 of 705) of unaffected women with family history of BC/ovarian cancer and 0.09% (one of 1,089) of unaffected women without family history; 38% of unaffected women with known BRCA mutation carried same mutation |
| Rodriguez100 | Cuba    | 2008               | 307 cases | 2.6% BRCA1/2 prevalence (10% familial cases, 10% age < 40 years) |
| Llanes-Fernández101 | Cuba      | 2006             | 23 cases | 23 BC samples exhibited strong expression of IL-10; IL-10 associated with some poor-prognosis tumor makers |

(Continued on following page)
Hormone receptor status (HRS) were conducted in Puerto Rico (four of five studies), whereas only a single study each was conducted in Cuba, Guadeloupe, Jamaica, and Trinidad. No studies of HRS were reported in the Bahamas or Suriname. The frequencies of estrogen receptor (ER)–positive and/or progesterone receptor (PR)–positive BC were similar for patients in Puerto Rico (ER positive, 65.9%; PR positive, 51.8%), Guadeloupe (ER positive/PR positive, 65.1%), and Jamaica (ER positive, 63%) and slightly higher than the frequencies for patients in Cuba (ER positive, 53%; PR positive, 49%) and Trinidad (ER positive, 54%; PR positive, 46%).52,53,57,59,66 The prevalence of triple-negative BC was reported only for patients with BC in Guadeloupe (14%) and Puerto Rico (17.3%).53,61

Case-control and cohort analyses were reported in six Caribbean countries, and common risk factors were identified: older age, late menarche, late parity, null parity, body size, family history, low DNA repair capacity, and low education level. However, the study in Jamaica noted that 54% of patients with BC did not have these common risk factors.72 Moreover, a higher percentage of cases were diagnosed in women between the ages of 45 and 54 years in Guadeloupe and Martinique.71

**BC outcomes and predictive factors.** Factors associated with BC outcomes were reported in four Caribbean countries (Cuba, French Guiana, Jamaica, and Trinidad). In accordance with the literature, negative HRS, advanced stage at diagnosis, positive lymph node status, and histologic type (infiltrating ductal carcinoma) were associated with poor prognosis or survival.76-82 Survival rates for patients with BC in Trinidad and Guyana were lower as compared with Caribbean-born patients with BC living in the United States (Brooklyn, NY).78 In Jamaica, one study reported that clinical staging was inadequate for the management of stage I BC and highlighted a need for consistent pathologic staging as well as use of other prognostic predictors to improve clinical outcomes in BC.82

**Behavioral risk factors.** Seven Caribbean countries contributed to six publications on behavioral factors relevant to BC.83-88 Screening was associated with younger age and church attendance in Grenada84 and general practitioner visits and provider communication in Guadeloupe and Martinique and the US Virgin Islands.85,88 In Grenada, perceived susceptibility to BC and perceived benefit of screening were more likely to be associated with women who frequently attended church.84 The only intervention study was conducted in Jamaica, where a theory-based educational intervention positively influenced knowledge of BC risk factors, symptoms, and types of screening and increased screening rates in screening-naïve women.86 The two behavioral studies involving BC cases were conducted in Cuba and Puerto Rico; in Cuba, family history of BC was perceived as a risk factor, but the concept of genetic risk had little meaning.85 In Puerto Rico, patients with BC had low physical activity, despite access to exercise equipment and facilities.87

**Barriers to early detection and BC treatment.** Seven Caribbean studies yielded eight publications

---

**Table 1. Key Findings From BC Research Studies of Caribbean Populations (Continued)**

| First Author | Country | Year of Publication | Study Size | Key Findings |
|--------------|---------|---------------------|------------|--------------|
| Dutil102 | Puerto Rico | 2012 | 23 cases | Six different deleterious mutations observed, including one mutation in BRCA1 and five mutations in BRCA2; three recurrent mutations (BRCA1 del exon1-2, BRCA2 4150G>T, and BRCA2 6027del4) account for > 70% of all BRCA mutations observed in this study population |
| Donenberg103 | Trinidad and Tobago | 2016 | 268 cases | 28 (10.4%) of 268 patients had mutation in BRCA1, BRCA2, or PALB2; majority were BRCA1 and BRCA2 mutations |

**Cost analysis**

| Ortiz-Ortiz104 | Puerto Rico | 2010 | 209 cases | Death resulting from BC among factors contributing most to productivity loss |

Abbreviations: BC, breast cancer; BSE, breast self-examination; DRC, DNA repair capacity; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GP, general practitioner; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; HRS, hormone receptor status; IDC, invasive ductal carcinoma; IL, interleukin; ILC, invasive lobular carcinoma; LC, lobular carcinoma; NA, not available; NOS, Not otherwise specified; OS, overall survival; PFS, progression-free survival; PR, progesterone receptor; TN, triple negative.
related to barriers to early detection and treatment. Lack of knowledge of signs and symptoms was highlighted in Haiti, and low frequency of breast self-examination, infrequent clinical breast examinations, and limited access to mammography were reported in Trinidad.

Health care cost was seen as a barrier to treatment in Haiti and a barrier to screening in Trinidad. In Trinidad, knowledge of family history as a risk factor for BC was common (76.8%), but knowledge of other risk factors was limited. Similarly, among BC survivors in Guadeloupe and Martinique, stress, genetic causes, and poor diet were the most frequently cited risk factors. In Puerto Rico, two studies respectively reported that underserved women diagnosed with BC were treated comparably to other patients and that referral by a physician was an important factor related to mammogram compliance.

Genetic risk factors and molecular biomarkers. Examinations of genetic and molecular biomarkers among Caribbean women were limited in comparison with US and European populations. BRCA1/2 mutations were the only genetic risk factors evaluated, with the highest prevalence reported in the Bahamas (approximately 27%). A Bahamian study showed that genetic testing of unaffected family members of patients with BC with BRCA1/2 mutations might be more effective if investigators use the proband as an intermediary to communicate with them. In addition, the only molecular biomarker investigated in outcomes of patients with BC was reported from Cuba, where a strong expression of interleukin-10 in tumors was associated with tumor markers of poor prognosis.

Cost analysis. The only Caribbean study on cost was a cost analysis of labor market productivity loss in Puerto Rico as a result of premature mortality from cancer. The study showed that death resulting from BC was included among cancer-related mortality causes that contributed the most to productivity loss.

DISCUSSION

Our literature review includes 92 publications of BC burden and research in native Caribbean women from 35 Caribbean nations over a span of 43 years and underlines the lack of precise field data as well as the limited research scope. The countries with the most research publications were countries with long-standing cancer registries and local scientific teams.

Most publications focused on describing cancer trends and clinicopathologic features (Fig 3), which were in line with GLOBOCAN estimates, placing BC as one of the top cancer sites for incidence and mortality among Caribbean women. However, several factors contribute to the weaknesses of these publications, such as the limited number of cancer registries with high-quality data and the rare focus on the impact of social and environmental factors on epidemiologic trends.

Moreover, availability of cancer screening programs and access to these programs play key roles in BC trends. Access to cancer screening programs varies not only according to an individual’s geographic residence but also among countries. A recent review of Caribbean cancer screening programs revealed that for 12 countries that have BC screening services available, mammography is not available in the public sector for more than half of them. It is then plausible that Caribbean women with private insurance and those with higher socioeconomic status may have better access to mammography. Furthermore, although traveling abroad to other countries for BC screening is unlikely, for those who can afford it, traveling abroad to other Caribbean countries (eg, Trinidad, Martinique, or Puerto Rico), the United States, the United Kingdom, or France for confirmation of a BC diagnosis or for treatment may be an option. All these factors may influence epidemiologic trends in BC. Therefore, BC incidence reported in Caribbean publications may have been underreported and subject to ascertainment bias caused by variability in data quality, completeness, socioeconomic status, BC screening access, and guidelines.

In terms of clinicopathologic status, few Caribbean studies described late stage at diagnosis, and a majority reported on ER-positive and/or PR-positive BC, with triple-negative BC averaging approximately 15% of all cases. As previously mentioned, these reports of clinicopathologic characteristics may have been influenced by limited access to and uptake of BC screening in the region. Furthermore, the availability of or access to HRS testing in each country may also have had an impact. Immunohistochemistry
(IHC) staining for BC receptors is part of the standard care in a few Caribbean countries. For others, IHC is not performed routinely except in the private sector, and for patients in Martinique and Guadeloupe, IHC is performed primarily in mainland France. Resolution of indeterminate HER2 results usually requires additional testing via in situ hybridization, and in these instances, samples are typically sent to the United States for testing. Therefore, some Caribbean countries may not experience the prognostic benefit of hormone receptor profiling, and although Caribbean publications report differences in the prevalence of ER and PR status among countries, these data may not necessarily reflect true biologic differences among Caribbean populations. These limitations should also be considered when reviewing published data from the Caribbean.

Although HRS and more advanced cancer stages are linked to poorer survival, as described by the few Caribbean studies on the subject, there are still multiple issues pertaining to cancer outcome and survival that have yet to be fully examined. Survival studies have almost exclusively been led in Trinidad, and virtually no information exists for other countries. Furthermore, apart from the Dominguez et al study describing disability-adjusted life-years in Cuban women, quality of life of Caribbean BC survivors after diagnosis, during treatment, or after returning to work has rarely been explored. Usual treatment regimens have not been described in detail, nor has access to such regimens. Behavioral factors, which play a major role in compliance with good health practices and screening, are also not well documented, nor is the impact of socioeconomic disparities within and among nations on health outcomes.

Age-specific incidence presented in this review further suggests that research studies are needed in the Caribbean to examine the contribution of hereditary versus sporadic BC. In the limited studies on molecular and genetic factors, mutations in BRCA1/2 genes were shown to influence early BC onset. However, there is an entire panel of highly penetrant (PALB2, TP53, CDH1, and STK11) and moderately penetrant germline (CHEK2, BRIP1, RAD51, and ATM) pathogenic variants and other genetic markers that are currently being examined in genome-wide association studies in populations other than those of the Caribbean. A comprehensive approach toward gene mutation and expression profiling in native Caribbean women must be adopted to characterize specific differences and improve cancer prognosis and outcome.

Key findings from Caribbean publications confirm similarities between the region and other countries, such as the United States. However, these publications also suggest within-region differences, and we have previously described plausible explanations such as differences in ethnic mixes, health care systems and economies, cancer registration, screening use. Our review also demonstrates that too little research has been conducted in the Caribbean to provide certified evidence of real or artifactual differences. Our review has highlighted significant research gaps in behavioral, molecular, genetic, and epidemiologic investigations of BC in native Caribbean women.

These disparities among nations, which might be linked to the geographic heterogeneity in BC incidence and mortality in the Caribbean, call for specifically tailored research and cancer control interventions that can only be addressed if the regional research portfolio is expanded to include more large-scale, targeted epidemiologic investigations with diverse research scopes. However, a more diverse research focus also requires adequate expertise and resources (human and infrastructural), which are not always readily available. Only those countries with strong local research teams (university campuses), strong public health policies in terms of cancer control and prevention, and reliable cancer registration and/or screening infrastructures seem able to publish or implement more diverse research studies. This is strongly supported by data shown in Figure 4. In those countries where research gaps exist or that experience challenges in diversifying their research scopes, improved cancer registration, capacity building, resource optimization and sustainability, and collaboration and communication among investigators will be essential in increasing research output and findings.

Today, a regional common unified strategy is necessary to address research needs among nations. Additional solutions lie in developing a strategic plan that includes setting standards for reinforced, sustainable, diverse, and efficient population research. This implies identifying
intra- and intercountry research specialties, needs, and priorities as well as existing tools, resources, stakeholders, and collaborators.

To that end, research consortia, such as the African Caribbean Cancer Consortium, represent a rich network of collaborators (existing and aspiring cancer registries, research and medical teams, governmental and institutional policymakers, and other cancer advocates and research teams at the local, regional, and international levels) and can leverage transdisciplinary expertise as a solution in addressing identified research gaps and promoting more diverse research opportunities in the Caribbean. We will promote research enhancement activities and training and establish research resources (eg, cancer and control cohorts with linked epidemiologic, clinical, and molecular and biomarker data). Regional investigations of BC risk and outcomes as well as tailored strategies for cancer prevention interventions in Caribbean women can be achieved.

DOI: https://doi.org/10.1200/JGO.18.00044
Published online on jgo.org on November 27, 2018.

AUTHOR CONTRIBUTIONS
Conception and design: Camille Ragin, Rishika Banydeen, Subhajit Dasgupta
Collection and assembly of data: Camille Ragin, Rishika Banydeen, Christine Zhang, Athena Ben, Victoria Calabrese, Nina N. Villa, Jade Reville, Shaoni Dasgupta, Mausumi Bandyopadhyay, Subhajit Dasgupta
Data analysis and interpretation: Camille Ragin, Rishika Banydeen, Christine Zhang, Delroy Louden, Subhajit Dasgupta
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Camille Ragin
No relationship to disclose

Rishika Banydeen
No relationship to disclose

Christine Zhang
No relationship to disclose

Athena Ben
No relationship to disclose

Victoria Calabrese
No relationship to disclose

Nina N. Villa
No relationship to disclose

Jade Reville
No relationship to disclose

Shaoni Dasgupta
No relationship to disclose

Mausumi Bandyopadhyay
No relationship to disclose

Delroy Louden
No relationship to disclose

Subhajit Dasgupta
No relationship to disclose

ACKNOWLEDGMENT
We thank Oscar Andrade, Saint James School of Medicine, Park Ridge, IL, who provided assistance with library services and Dorothy Donis Conors of Anguilla for suggesting and encouraging the pursuit of this project.

Affiliations
Camille Ragin, Fox Chase Cancer Center, Temple Health; Camille Ragin, African Caribbean Cancer Consortium, Philadelphia, PA; Rishika Banydeen, Centre Hospitalier Universitaire de Martinique; Rishika Banydeen, African Caribbean Cancer Consortium, Fort-de-France, Martinique; Christine Zhang, Athena Ben, Victoria Calabrese, Nina N. Villa, Jade Reville, and Subhajit Dasgupta, Saint James School of Medicine; Subhajit Dasgupta, African Caribbean Cancer Consortium, The Quarter; Delroy Louden, Anguilla Community College, George Hill, Anguilla; Shaoni Dasgupta, Academic Magnet High School; and Mausumi Bandyopadhyay, Trident Technical College, Charleston, SC.

Support
Supported in part by National Cancer Institute (NCI) Grant No. P30 CA006927; by NCI Grants No. P20 CA210294 and R13 CA192672-03 (C.R.); and by an internal project studying prevalence of breast cancer in the Anguillan population (Saint James School of Medicine [2014-2015]; S. Dasgupta).
REFERENCES

1. Razzaghi H, Quesnel-Crooks S, Sherman R, et al: Leading causes of cancer mortality: Caribbean region, 2003-2013. MMWR Morb Mortal Wkly Rep 65:1395-1400, 2016

2. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 11. http://globocan.iarc.fr/Default.aspx

3. Chan DS, Vieira AR, Aune D, et al: Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901-1914, 2014

4. Rudolph A, Chang-Claude J, Schmidt MK: Gene-environment interaction and risk of breast cancer. Br J Cancer 114:125-133, 2016

5. Sapkota Y: Germline DNA variations in breast cancer predisposition and prognosis: A systematic review of the literature. Cytogenet Genome Res 144:77-91, 2014

6. Zheng Y, Ogundiran TO, Falusi AG, et al: Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis 34:1520-1528, 2013

7. Hung MC, Ekwueme DU, Rim SH, et al: Racial/ethnicity disparities in invasive breast cancer among younger and older women: An analysis using multiple measures of population health. Cancer Epidemiol 45:112-118, 2016

8. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676, 2004

9. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000

10. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001

11. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393-10398, 2003

12. Curtis C, Shah SP, Chin SF, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352, 2012

13. Consedine NS, Tuck NL, Ragin CR, et al: Beyond the black box: A systematic review of breast, prostate, colorectal, and cervical screening among native and immigrant African-descent Caribbean populations. J Immigr Minor Health 17:905-924, 2014

14. Brooks SE, Wolff C: Cancer in the Caribbean and environs: A comparison of age-standardized rates for 9 population groups. West Indian Med J 41:103-110, 1992

15. Ivey MA, Legall G, Boisson EV, et al: Mortality trends and potential years of life lost in the English and Dutch-speaking Caribbean, 1985-2000. West Indian Med J 57:122-131, 2008

16. Luciani S, Cabanes A, Prieto-Lara E, et al: Cervical and female breast cancers in the Americas: Current situation and opportunities for action. Bull World Health Organ 91:640-649, 2013

17. Robles SC, Galanis E: Breast cancer in Latin America and the Caribbean. Rev Panam Salud Publica 11:178-185, 2002

18. Bosetti C, Malvezzi M, Chatenoud L, et al: Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol 16:489-511, 2005

19. Chatenoud L, Bertuccio P, Bosetti C, et al: Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol 25:1843-1853, 2014

20. Di Sibio A, Abriata G, Forman D, et al: Female breast cancer in Central and South America. Cancer Epidemiol 44:S110-S120, 2016 (suppl 1)

21. Simon LC: Cancer incidence and mortality in Antigua/Barbuda. West Indian Med J 40:74-80, 1991
22. Brathwaite AF: Cancer patterns and trends in the Bahamas. Bull Pan Am Health Organ 18:10-18, 1984
23. Brathwaite AF, Brathwaite N, del Riego A: Epidemiological profile of cancer for Grand Bahama residents: 1988-2002. West Indian Med J 56:26-33, 2007
24. Hennis AJ, Hambleton IR, Wu SY, et al: Breast cancer incidence and mortality in a Caribbean population: Comparisons with African-Americans. Int J Cancer 124:429-433, 2009
25. Dallaire F, Dewailly E, Rouja P: Cancer incidence and mortality rates in Bermuda. West Indian Med J 58:367-374, 2009
26. Martín AA, Galán YH, Rodríguez AJ, et al: The Cuban National Cancer Registry: 1986-1990. Eur J Epidemiol 14:287-297, 1998
27. Graupera Boschmonar MC, Jiménez Chaviano PJ, Martín García AA, et al: Trends in survival rates of cancer in Cuba. Eur J Epidemiol 15:521-528, 1999
28. Galán Y, Fernández L, Torres P, et al: Trends in Cuba’s cancer incidence (1990 to 2003) and mortality (1990 to 2007). MEDICC Rev 11:19-26, 2009
29. Garrote LF, Alvarez YG, Babie PT, et al: Cancer survival in Cuba, 1994-1995. IARC Sci Publ 162:89-95, 2011
30. Domínguez E, Santana F, Seuc AH: Disability-adjusted life years for breast and reproductive system cancers in Cuban women of child bearing age. MEDICC Rev 16:8-13, 2014
31. Shai D: Cancer mortality in Cuba and among the Cuban-born in the United States: 1979-81. Public Health Rep 106:68-73, 1991
32. Asulin Y, McCann TJ, McCarty CW, et al: Cancer incidence and mortality in Grenada 1990-2000. West Indian Med J 53:368-373, 2004
33. Best Plummer WS, Persaud P, Layne PJ: Ethnicity and cancer in Guyana, South America. Infect Agent Cancer 4:S7, 2009 (suppl 1)
34. Harris M: Carcinoma of the female breast in Jamaica. Trop Geogr Med 29:213-222, 1977
35. Brooks SE, Wolff C: 30-year cancer trends in Jamaica: Kingston & St. Andrew (1958-1987). West Indian Med J 40:134-138, 1991
36. Brooks SE, Hanchard B, Wolff C, et al: Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 1988-1992. West Indian Med J 44:102-105, 1995
37. Hanchard B, Blake G, Wolff C, et al: Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 1993-1997. West Indian Med J 50:123-129, 2001
38. Blake G, Hanchard B, Mitchell K, et al: Jamaica cancer mortality statistics, 1999. West Indian Med J 51:64-67, 2002
39. Gibson TN, Blake G, Hanchard B, et al: Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 1998-2002. West Indian Med J 57:81-89, 2008
40. Gibson TN, Hanchard B, Waugh N, et al: Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 2003-2007. West Indian Med J 59:456-464, 2010
41. Dieye M, Veronique-Baudin J, Draganescu C, et al: Cancer incidence in Martinique: A model of epidemiological transition. Eur J Cancer Prev 16:95-101, 2007
42. Freni SC, Freni-Titulaer LW: Cancer incidence in the Netherlands Antilles: A survey covering the period 1968-1979. Cancer 48:2535-2541, 1981
43. Torres-Cintrón M, Ortiz AP, Ortiz-Ortiz KJ, et al: Using a socioeconomic position index to assess disparities in cancer incidence and mortality, Puerto Rico, 1995-2004. Prev Chronic Dis 9:E15, 2012
44. O’Neil ME, Henley SJ, Singh SD, et al: Invasive cancer incidence: Puerto Rico, 2007-2011. MMWR Morb Mortal Wkly Rep 64:389-393, 2015
45. Nazario CM, Figueroa-Vallés N, Rosario RV: Breast cancer patterns and lifetime risk of developing breast cancer among Puerto Rican females. P R Health Sci J 19:7-13, 2000
46. Martínez I, Torres R, Frías Z: Cancer incidence in the United States and Puerto Rico. Cancer Res 35:3265-3271, 1975
47. Ortiz AP, Soto-Salgado M, Calo W, et al: Disparities in breast cancer in Puerto Rico and among Hispanics, non-Hispanic whites, and non-Hispanics blacks in the United States, 1992-2004. Breast J 16:666-668, 2010
48. van Leeuwaarde RS, Vrede MA, Henar F, et al: A nationwide analysis of incidence and outcome of breast cancer in the country of Surinam, during 1994-2003. Breast Cancer Res Treat 128:873-881, 2011
49. Naraynsingh V, Hariharan S, Dan D, et al: Trends in breast cancer mortality in Trinidad and Tobago: A 35-year study. Cancer Epidemiol 34:20-23, 2010
50. Warner WA, Morrison RL, Lee TY, et al: Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. Cancer Med 4:1742-1753, 2015
51. Mungrue K, Chase H, Gordon J, et al: Breast cancer in the Bahamas in 2009-2011. Breast Cancer (Auckl) 10:45-52, 2016
52. Alvarez Goyanes RI, Escobar Pérez X, Camacho Rodríguez R, et al: Hormone receptors and other prognostic factors in breast cancer in Cuba. MEDICC Rev 12:36-40, 2010
53. Deloumeaux J, Gaumond S, Bhakkan B, et al: Incidence, mortality and receptor status of breast cancer in African Caribbean women: Data from the cancer registry of Guadeloupe. Cancer Epidemiol 47:42-47, 2017
54. Pott G, Hanchard B, Fletcher PR: Cancer of the breast: A ten-year review at the University Hospital of the West Indies. West Indian Med J 27:222-226, 1978
55. Shirley SE, Mitchell DI, Soares DP, et al: Clinicopathologic features of breast disease in Jamaica: Findings of the Jamaican Breast Disease Study, 2000-2002. West Indian Med J 57:90-94, 2008
56. Shirley SE, Sinclair PA, Stennett MA, et al: The pathology of breast cancer in Jamaica: The National Public Health Laboratory study. West Indian Med J 59:177-181, 2010
57. Alfred R, Chin SN, Williams E, et al: The prevalence and significance of oestrogen receptor (ER) positivity in breast cancer at the University Hospital of the West Indies, Jamaica. West Indian Med J 61:795-801, 2012
58. Peredo R, Sastre G, Serrano J, et al: Her-2/neu oncogene expression in Puerto Rican females with breast cancer. Cell Mol Biol (Noisy-le-grand) 47:1025-1032, 2001
59. Colón E, Reyes JS, González Keelan C, et al: Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico. P R Health Sci J 21:299-303, 2002
60. Giraldo-Jiménez MY, Cabanillas F, Negrón V, et al: Triple negative breast cancer: A retrospective study of Hispanics residing in Puerto Rico. P R Health Sci J 31:45-51, 2012
61. Ortiz AP, Frías O, Pérez J, et al: Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico. Cancer Med 2:343-350, 2013
62. Agosto-Arroyo E, Climent C, Vélez R, et al: Expression of basal-like biomarkers in triple negative invasive breast carcinoma in Puerto Rico. P R Health Sci J 34:89-92, 2015
63. Brathwaite AF: Breast cancer in Surinam. Trop Geogr Med 31:81-85, 1979
64. Raju GC, Naraynsingh V: Breast cancer in West Indian women in Trinidad. Trop Geogr Med 41:257-260, 1989
65. Jack N, Edwards J, Dhanessar W, et al: A study of HTLV-I infection and breast cancers in Trinidad and Tobago. Int J Cancer 85:298-299, 2000
66. Rao AV, Mohammed WA, Ragoonian C, et al: Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women. West Indian Med J 51:4-9, 2002
67. Mungrue K, Ramdath J, Ali S, et al: Challenges to the control of breast cancer in a small developing country. Breast Cancer (Auckl) 8:7-13, 2014
68. Dindyal S, Ramdass MJ, Naraynsingh V, et al: Relationship of ethnicity and histologic type of breast carcinoma in a West Indian population. Breast J 10:266, 2004
69. Nemesure B, Wu SY, Hennis A, et al: Body size and breast cancer in a black population: The Barbados National Cancer Study. Cancer Causes Control 20:387-394, 2009
70. Fernández L, Buch ML, Molina A, et al: Risk factors in mass screening for breast cancer, multivariate analysis of data from the Cuban diagnosis pilot study. Neoplasma 33:535-541, 1986
71. Kadhel P, Multigner L: Age at breast cancer diagnosis in populations of African and European ancestry. Breast J 20:180-184, 2014
72. Brady-West DC, Graham SA: Prevalence of risk factors in breast cancer patients at the University Hospital of the West Indies. West Indian Med J 49:161-163, 2000
73. Santiago E, González MJ, Matos MI, et al: Association between dietary fat and breast cancer in Puerto Rican postmenopausal women attending a breast cancer clinic. P R Health Sci J 17:235-241, 1998
74. Morales L, Alvarez-Garriga C, Matta J, et al: Factors associated with breast cancer in Puerto Rican women. J Epidemiol Glob Health 3:205-215, 2013
75. Joseph D, Thorpe L, Annandsingh C, et al: Breast cancer diagnosis from screening in Trinidad and Tobago: Opportunities for cancer prevention. J Immigr Minor Health 16:409-415, 2014
76. Naraynsingh V, Rambally R, Maharaj R, et al: Early hospital discharge following breast cancer surgery in the West Indies: A Trinidad study. J Natl Med Assoc 103:754-756, 2011
77. Camacho-Rivera M, Ragin C, Roach V, et al: Breast cancer clinical characteristics and outcomes in Trinidad and Tobago. J Immigr Minor Health 17:765-772, 2015
78. Taioli E, Attong-Rogers A, Layne P, et al: Breast cancer survival in women of African descent living in the US and in the Caribbean: Effect of place of birth. Breast Cancer Res Treat 122:515-520, 2010
79. Roué T, Labbé S, Bellardo S, et al: Predictive factors of the survival of women with invasive breast cancer in French Guiana: The burden of health inequalities. Clin Breast Cancer 16:e113-e118, 2016
80. Skoog L, Wallgren A, Pascual MR, et al: Factors associated with prognosis in human breast cancer: VII. A comparison between a Cuban and a Swedish study. Neoplasma 34:587-594, 1987
81. Ríos MA, Macías A, Pérez R, et al: Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8:173-176, 1988
82. Walters JP: Outcome of stage I carcinoma of the breast at the University Hospital of the West Indies (1982-1988). West Indian Med J 43:127-129, 1994
83. Gibbon S: Family medicine, ‘La Herencia’ and breast cancer: Understanding the (dis)continuities of predictive genetics in Cuba. Soc Sci Med 72:1784-1792, 2011
84. Delpech PA, Haynes-Smith G: Breast Self-examination and health beliefs in Grenadian women. Cancer Nurs 38:E54-E59, 2015
85. Menvielle G, Dugas J, Richard JB, et al: Socioeconomic and healthcare use-related determinants of cervical, breast and colorectal cancer screening practice in the French West Indies. Eur J Cancer Prev 27:269-273, 2018
86. Anakwenze CP, Coronado-Interis E, Aung M, et al: A theory-based intervention to improve breast cancer awareness and screening in Jamaica. Prev Sci 16:578-585, 2015
87. Tirado-Gómez M, Hughes DC, González-Mercado V, et al: Physical activity in Puerto Rican breast cancer survivors. P R Health Sci J 35:62-68, 2016
88. Underwood S, Johnson ER, Callwood G, et al: Promoting breast health among women in the U.S. Virgin Islands: A focused study of the needs of Caribbean women. J Natl Black Nurses Assoc 18:53-62, 2007
89. Peltzer K, Pengpid S: Awareness of breast cancer risk among female university students from 24 low, middle income and emerging economy countries. Asian Pac J Cancer Prev 15:7875-7878, 2014
90. Kadhel P, Schuster C, Grossat N, et al: Causal attribution of breast cancer by survivors in French West Indies. J Cancer Educ 33:317-320, 2018
91. Sharma K, Costas A, Damuse R, et al: The Haiti breast cancer initiative: Initial findings and analysis of barriers-to-care delaying patient presentation. J Oncol 2013:206367, 2013
92. O’Neill KM, Mandigo M, Pyda J, et al: Out-of-pocket expenses incurred by patients obtaining free breast cancer care in Haiti: A pilot study. Surgery 158:747-755, 2015
93. Chirikos TN, López-Garcia J, Cintrón Vargas C, et al: Evaluation of breast cancer care under Puerto Rico’s health care reform. J Health Care Poor Underserved 18:116-138, 2007
94. Sánchez Ayéndez M, Suárez-Pérez E, Vázquez MO, et al: Knowledge and beliefs of breast cancer among elderly women in Puerto Rico. P R Health Sci J 20:351-359, 2001
95. Modeste NN, Caleb-Drayton VL, Montgomery S: Barriers to early detection of breast cancer among women in a Caribbean population. Rev Panam Salud Publica 5:152-156, 1999
96. Chirikos TN, López-Garcia J, Cintrón Vargas C, et al: Evaluation of breast cancer care under Puerto Rico’s health care reform. J Health Care Poor Underserved 18:116-138, 2007
97. Akbari MR, Donenberg T, Lunn J, et al: The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet 85:64-67, 2014
98. Trottier M, Lunn J, Butler R, et al: Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. Clin Genet 88:182-186, 2015
99. Trottier M, Lunn J, Butler R, et al: Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. Clin Genet 89:328-331, 2016
100. Rodriguez RC, Esperon AA, Ropero R, et al: Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer 7:275-279, 2008
101. Llanes-Fernández L, Alvarez-Goyanes RI, Arango-Prado MC, et al: Relationship between IL-10 and tumor markers in breast cancer patients. Breast 15:482-489, 2006
102. Dutil J, Colon-Colon JL, Matta JL, et al: Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet 205:242-248, 2012
103. Donenberg T, Ahmed H, Royer R, et al: A survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago. Breast Cancer Res Treat 159:131-138, 2016
104. Ortiz-Ortiz KJ, Pérez-Irizarry J, Marín-Centeno H, et al: Productivity loss in Puerto Rico’s labor market due to cancer mortality. P R Health Sci J 29:241-249, 2010
105. Dohn AL, Chávez A, Dohn MN, et al: Changes in health indicators related to health promotion and microcredit programs in the Dominican Republic. Rev Panam Salud Publica 15:185-193, 2004
106. Banydeen R, Rose AM, Martin D, et al: Advancing cancer control through research and cancer registry collaborations in the Caribbean. Cancer Contr 22:520-530, 2015
107. Franklin RA, Simeon DT: Urgent need to strengthen and expand screening and other cancer control programs in the CARICOM Caribbean. Cancer Causes Control 28:1177-1185, 2017
108. Campeau PM, Foulkes WD, Tischkowitz MD: Hereditary breast cancer: New genetic developments, new therapeutic avenues. Hum Genet 124:31-42, 2008
109. Walsh T, Casadei S, Coats KH, et al: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379-1388, 2006
110. Rahman N, Seal S, Thompson D, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165-167, 2007

111. Central Intelligence Agency: The World Factbook 2013-14. https://www.cia.gov/library/publications/the-world-factbook/index.html

112. Pan American Health Organization: Health in the Americas: Scientific and technical publication No. 622 volume 1 (regional). http://iris.paho.org/xmlui/bitstream/handle/123456789/3009/health-americas-2007-vol-1.pdf?sequence=2

113. Ragin CC, Taioli E, McFarlane-Anderson N, et al: African-Caribbean Cancer Consortium for the study of viral, genetic and environmental cancer risk factors. Infect Agent Cancer 2:17-22, 2007
The CARICOM (Caribbean Community) countries include English, Dutch, French, and Latin Caribbean nations that are islands, as well as countries on the continents of Central and South America: Anguilla, Antigua and Barbuda, the Bahamas, Barbados, Belize, Bermuda, the British Virgin Islands, the Cayman Islands, Cuba, Dominica, the Dominican Republic, French Guiana, Grenada, Guadeloupe, Guyana, Haiti, Jamaica, Martinique, Montserrat, the Netherlands Antilles (Aruba, Bonaire, Curaçao, Saba, St Eustatius, and the Dutch half of St Martin [Sint Maarten]), Puerto Rico, St Barthélemy, St Kitts and Nevis, St Lucia, the French half of St Martin (Saint-Martin), St Vincent and the Grenadines, Suriname, Trinidad and Tobago, the Turks and Caicos, and the US Virgin Islands.